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Pathogenesis
A speciﬁc group of diarrhea and enteritis cases occurring in
the course of antibiotic therapy is referred to as antibiotic-
associated diarrhea and enterocolitis. The antibiotic admin-
istered disturbs normal intestinal ﬂora, and bacterial
species resistant to the antibiotic used multiply extraordi-
narily, resulting in the development of this disease. Clos-
tridium difﬁcile is frequently involved in this condition [1].
Involvements of Staphylococcus aureus (particularly,
MRSA), Klebsiella oxytoca, and Candida species have also
been reported, although clinical pictures differ among these
microorganisms [2]. Antibiotic-associated diarrhea and
enterocolitis associated with C. difﬁcile alone will be
described below.
Antibiotic-associated diarrhea and enterocolitis associ-
ated with overgrowth of toxigenic C. difﬁcile occur fre-
quently, and may develop into pseudomembranous colitis
in severe cases. Most cases have a speciﬁc form of infec-
tious colitis which manifests during antibiotic therapy in
the inpatient setting. It should be noted that the diagnosis
and treatment strategy for this disease differs from that for
other forms of infectious enterocolitis.
C. difﬁcile is a spore-forming obligate anaerobe indig-
enous to the intestine in 5–10% of healthy adults [3].
Among patients on antibiotic therapy, about 30% are car-
riers of this bacterium [4]. The hospital setting is apt to be
contaminated with C. difﬁcile spores, and it has been
speculated that a majority of patients with C. difﬁcile
enteritis became carriers during hospitalization [4, 5].
C. difﬁcile produces two toxins, i.e., toxin A (enterotoxin)
and toxin B (cytotoxin), which are encoded upstream and
downstream by the same gene, and injure the mucosal
epithelium of the intestine by decomposing cytoskeletal
myosin. In recent years, the presence of a binary toxin that
enhances the actions of these two toxins has been described
[6].
It is generally known that this form of disease is more
common in the elderly, and host immunocompetence is
related to the onset and recurrence/recrudescence of this
disease.
Clinical manifestations
This disease manifests with diarrhea associated to antibi-
otic therapy. Although the major causative antimicrobial
agents are cephems and clindamycin (CLDM), cases rela-
ted to almost all antibiotics, i.e., penicillins and carba-
penems, have been reported [2]. In addition, cases related
to respiratory quinolones have recently been increasing [6].
Watery diarrhea, purulent, mucous and bloody stools,
and loose stools are seen. This disease may occur after the
discontinuation of antibiotic therapy or immediately after
the initiation of such therapy. Mild cases exhibit diarrheal
symptoms alone, providing nonspeciﬁc ﬁndings of
enterocolitis on endoscopy and presenting only a minor
systemic inﬂammatory response. When the condition
becomes more severe, developing into pseudomembranous
lesions, marked leukocytosis (sometimes exceeding
20,000–30,000/lL) and elevated CRP are present, a con-
dition likely to be mistaken for aggravation of the various
preceding types of infections. In serious cases, paralytic
ileus or toxic megacolon may occur, without accompany-
ing diarrheal symptoms. In prolonged cases, hypoprotein-
emia and electrolyte imbalance are present.
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Diagnosis
This disease should be suspected if diarrhea occurs during
treatment for infections with antimicrobial agents. A
deﬁnitive diagnosis is obtained by bacteriologic examina-
tion of feces, toxin assays and colonoscopy.
Stool cultures
Anaerobic stool cultures using a selective medium such as
CCFA should be carried out. Quantitative cultures are
desirable to determine pathogenic signiﬁcance. Clinical
manifestation often occurs at levels of 105–108 CFU/g of
stool. Two to three days are required to obtain culture
results.
Toxin assays
Although the toxin A (enterotoxin) assay, by the loop test,
and the toxin B (cytotoxin) assay, for assessing cytopathic
effects, are standard assays, both require specialized
facilities. The following examinations are commonly used
in the clinical setting.
CD check D1
This test was formerly widely employed because it was
regarded as a simple latex agglutination test using antitoxin
antibody. However, it was later found that a metabolic
enzyme (glutamate dehydrogenase) produced by C. difﬁcile
would be measured concomitantly, and now the test is thus
considered to be inadequate for detecting toxins. However,
since the results reﬂect the size of the bacterial population,
and no complicated techniques are required, it is still of
some value as a rapid diagnostic test.
Toxin A detection kit
In recent years, immunological assay kits for measurement
of toxin A (Uniquick, VIDAS CDA2, etc.) have been
commonly used. However, in the meantime, toxin A-neg-
ative and toxin B-positive cases have been reported.
Toxin A/B detection kit
A test kit that detects both toxin A and toxin B (TOX A/B
QUIK CHEK ‘Nissui Pharmaceutical Co., Ltd.’) became
available in June 2007.
Genetic test
Although methods for detecting toxin-producing genes by
nested PCR or real-time PCR techniques have been
developed, they are not yet available in the clinical labo-
ratory setting.
Incidentally, the prevalence of C. difﬁcile strains that
produce binary toxin, so-called ‘‘third toxin,’’ has recently
been reported in Europe and the US [6].
Diagnostic imaging
Colonoscopy
Pseudomembranous lesions, which, in practical terms, are
speciﬁc to C. difﬁcile enteritis, are more conspicuous on the
anal side and provide an adequate reﬂection of the severity
of the disease. Therefore, the clinical usefulness of colon-
oscopy has been attracting attention. Although the inva-
siveness of this examination is a concern, it is useful when
bacteriologic examination is very difﬁcult or not feasible.
Observation of toxic megacolon on abdominal radiography
and mucosal folds on CT is occasionally useful.
Treatment
When providing antibiotics, adequate therapy should be
selected, and the complication of diarrhea should be
properly predicted to achieve early diagnosis and early
treatment before enteritis becomes serious.
Elimination of Clostridium difﬁcile
VCM has potent antibacterial activity against vegetative
cells of C. difﬁcile, and there are no resistant strains.
Therefore, this antibiotic is currently in widespread use.
VCM is given orally for about 1–2 weeks at 0.5–2 g/day in
4 divided doses. If oral administration is difﬁcult, the drug
should be administered via a nasogastric tube or enema.
Because VCM is expensive, metronidazole is the ﬁrst
choice in Europe and the US. If there is no response to
metronidazole, VCM is used. In Japan, the use of metro-
nidazole in cases of this disease is not covered by health
insurance.
Recurrence/recrudescence is noted after therapy in about
20% of patients. C. difﬁcile surviving in the form of spores
may germinate and develop into vegetative cells after
VCM or metronidazole is discontinued, or the patient may
be re-infected, resulting in recurrence/recrudescence. The
efﬁcacy of intermittent administration of VCM in such
recurrent cases has been reported [7–9]. This is a modiﬁ-
cation of intermittent sterilization of spore-forming bacte-
ria. Namely, an anti-C. difﬁcile drug is administered
intermittently during the period from germination of spores
until development into vegetative cells. Although speciﬁc
procedures vary widely among patients, a reported example
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is administration of an anti-C. difﬁcile drug every 3 days at
decreasing doses for a 2- to 4-week period.
Recovery of intestinal ﬂora
In normal intestinal ﬂora, C. difﬁcile is inhibited by other
bacteria comprising the intestinal ﬂora. The major reason
for the development and recrudescence of enterocolitis is
disturbance of the intestinal ﬂora. Normalization of bac-
terial ﬂora is the most important goal in prevention and
treatment of this disease. Therefore, the key is to discon-
tinue the antibiotic therapy that caused diarrhea, and
2–30% of patients with C. difﬁcile enteritis will be cured
without any other treatment. Efforts have been made to
utilize genus Saccharomyces, clostridium butyricum, and
lactic acid producing bacteria such as Lactobacillus or
Biﬁdobacterium, with expectation of beneﬁts from these
probiotics [10].
Prevention
Proper and cautious use of antibiotics that can cause diar-
rhea is desirable. In addition, it is possible that contami-
nation of the hospital environment with C. difﬁcile spores
is related to the development of this disease, and that
maintaining a clean hospital environment is therefore
required.
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